Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2018 2
2019 3
2021 4
2022 1
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G, Brixner D, Biskupiak J, Burgoyne D, Arondekar B, Deal LS, Quek RG, Niyazov A. Oderda G, et al. J Manag Care Spec Pharm. 2022 Feb;28(2):188-195. doi: 10.18553/jmcp.2021.21223. Epub 2021 Nov 22. J Manag Care Spec Pharm. 2022. PMID: 34806908
DISCLOSURES: Pfizer provided funding for this research, and employees of Pfizer contributed to the development of the survey instrument, were involved in the interpretation of the data, and contributed to the discussion and output as authors. Biskupiak, Oderda, and …
DISCLOSURES: Pfizer provided funding for this research, and employees of Pfizer contributed to the development of the survey instrument, wer …
Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D, Biskupiak J, Oderda G, Burgoyne D, Malone DC, Arondekar B, Niyazov A. Brixner D, et al. J Manag Care Spec Pharm. 2021 Aug;27(8):1096-1105. doi: 10.18553/jmcp.2021.27.8.1096. J Manag Care Spec Pharm. 2021. PMID: 34337998 Free PMC article.
Arondekar and Niyazov are employees of Pfizer; Oderda, Biskupiak, and Brixner are managers of Millcreek Outcomes Group and were paid as consultants on this project. ...
Arondekar and Niyazov are employees of Pfizer; Oderda, Biskupiak, and Brixner are managers of Millcreek Outcomes Group …
Payer perceptions on the use of economic models in oncology decision making.
Biskupiak J, Oderda G, Brixner D, Burgoyne D, Arondekar B, Niyazov A. Biskupiak J, et al. J Manag Care Spec Pharm. 2021 Nov;27(11):1560-1567. doi: 10.18553/jmcp.2021.27.11.1560. J Manag Care Spec Pharm. 2021. PMID: 34714111 Free PMC article.
Arondekar and Niyazov are employed by Pfizer. Biskupiak, Oderda, and Brixner are managers of Millcreek Outcomes Group and were paid as consultants on this project. ...
Arondekar and Niyazov are employed by Pfizer. Biskupiak, Oderda, and Brixner are managers of Millcreek Outcomes Group a …
Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
Biskupiak J, Oderda G, Brixner D, Tang D, Zacker C, Dalal AA. Biskupiak J, et al. J Manag Care Spec Pharm. 2019 Aug;25(8):859-866. doi: 10.18553/jmcp.2019.25.8.859. J Manag Care Spec Pharm. 2019. PMID: 31347980 Free PMC article.
Tang was employed by Novartis during this study; Zacker and Dalal are employed by Novartis and own company stock. Biskupiak, Brixner, and Oderda received payment from Novartis for this study. Brixner serves as a consultant for Millcreek Outcomes Group …
Tang was employed by Novartis during this study; Zacker and Dalal are employed by Novartis and own company stock. Biskupiak, Brixn …
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R, May JR, Suri G, Young K, Brixner D, Oderda G, Biskupiak J, Tang D, Bhattacharyya S, Mishra D, Bhattacharyya D, Dalal AA. Mistry R, et al. J Manag Care Spec Pharm. 2018 Jun;24(6):514-523. doi: 10.18553/jmcp.2018.24.6.514. J Manag Care Spec Pharm. 2018. PMID: 29799329 Free PMC article.
Tang and Dalal hold stock in Novartis. Brixner, Oderda, and Biskupiak were paid by Millcreek Outcomes Group as consultants for work on this project. Brixner has also consulted for AstraZeneca, UCB, Regeneron, and Abbott....
Tang and Dalal hold stock in Novartis. Brixner, Oderda, and Biskupiak were paid by Millcreek Outcomes Group as consulta …
Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational Therapies.
Brixner D, Woodward TC, Seifter N, Biskupiak J, Marciniak M, Neumann P, Oderda G. Brixner D, et al. J Manag Care Spec Pharm. 2019 Feb;25(2):164-173. doi: 10.18553/jmcp.2019.25.2.164. J Manag Care Spec Pharm. 2019. PMID: 30698089 Free PMC article.
DISCLOSURES: This study was funded by GlaxoSmithKline (GSK). Brixner, Oderda, and Biskupiak are principals of Millcreek Outcomes Group, a consultancy that received funding from GSK to conduct this study. ...
DISCLOSURES: This study was funded by GlaxoSmithKline (GSK). Brixner, Oderda, and Biskupiak are principals of Millcreek …
14 results